Galena Biopharma (GALE) Initiates NeuVax Phase 3
Tweet
Share
E-mailGet Alerts GALE Hot Sheet
Join SI Premium – FREE
Galena Biopharma, Inc. (Nasdaq: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments, today announced the initiation of its Phase 3 PRESENT trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients (often referred to as HER2 negative) in the adjuvant setting to prevent recurrence.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug
- Optex Systems wins $0.4M infrared window order, eyes follow-on deals
- Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
